title: Poly-L-lactic acid for facial lipoatrophy in HIV.
abstract: OBJECTIVE
  To review the clinical data for poly-L-lactic acid, a synthetic polymer used as an intradermal injection for the treatment of HIV associated facial fat loss (lipoatrophy).
  
  
  METHODS
  A literature search was performed using MEDLINE (1966-August 2006). The search was limited to articles published in English and used the key words polylactic acid, polylactides, degradation, lipodystrophy, lipoatrophy, and HIV/AIDS. Dermik Laboratories was contacted to obtain unpublished information. Additional articles were retrieved from citations of selected references.
  
  
  METHODS
  Relevant information on the pharmacology, pharmacokinetics, safety, and efficacy of poly-L-lactic acid from clinical trials were selected.
  
  
  RESULTS
  Poly-L-lactic acid (Sculptra) is a biocompatible, biodegradable, synthetic polymer able to be tailored into various desired morphologic features. It is approved by the Food and Drug Administration for the correction of facial lipoatrophy in people with HIV. Six clinical trials have evaluated the use of intradermal injections of poly-L-lactic acid. Results showed that cutaneous thickness is improved in patients receiving poly-L-lactic acid. Adverse effects included nodule and hematoma formation, as well as pain at the injection site.
  
  
  CONCLUSIONS
  Poly-L-lactic acid offers a treatment alternative for patients with HIV-associated lipoatrophy. Further research is required in nonwhite populations.
authors.affiliation: Infectious Diseases, Thomas Jefferson University Hospital, Philadelphia, PA 19107-4824, USA. Claudine.el-beyrouty@mail.tju.edu
authors.forename: Claudine
authors.initials: C
authors.lastname: El-Beyrouty
authors.forename: Vanthida
authors.initials: V
authors.lastname: Huang
authors.forename: Courtney J
authors.initials: CJ
authors.lastname: Darnold
authors.forename: Patrick G
authors.initials: PG
authors.lastname: Clay
mesh_terms: D005145:Face / Q000473:pathology; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D015497:HIV-1; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007279:Injections, Subcutaneous; D019344:Lactic Acid / Q000008:administration & dosage*; D011091:Polyesters; D011108:Polymers / Q000008:administration & dosage*
chemical_list: D011091:Polyesters; D011108:Polymers; D019344:Lactic Acid; C033616:poly(lactide)